Risk of Acute Myocardial Infarction Among New Users of Allopurinol According to Serum Urate Level: A Nested Case-Control Study

Sara Rodríguez-Martín 1,2,†, Francisco J. de Abajo 1,2,*,†, Miguel Gil 3, Diana González-Bermejo 3, Antonio Rodríguez-Miguel 1,2, Ramón Mazzucchelli 4, Alberto García-Lledó 5,6 and Luis A. García-Rodríguez 7

1 Clinical Pharmacology Unit, University Hospital Príncipe de Asturias, Alcalá de Henares, 28805 Madrid, Spain; rodriguezmartin.sara@gmail.com (S.R.-M.); antonio.hupa@gmail.com (A.R.-M.); dbarreirahdez@gmail.com (D.B.-H.)
2 Department of Biomedical Sciences (Pharmacology Sector), University of Alcalá (IRYCIS), Alcalá de Henares, 28805 Madrid, Spain
3 Division of Pharmacoepidemiology and Pharmacovigilance, Spanish Agency for Medicines and Medical Devices (AEMPS), 28022 Madrid, Spain; mgilg@aemps.es (M.G.); dgonzalezb@aemps.es (D.G.-B.)
4 Department of Rheumatology, University Hospital Fundación Alcorcón, 28922 Alcorcón, Madrid, Spain; RMazzucchelli@fhalcorn.es
5 Department of Cardiology, University Hospital Príncipe de Asturias, Alcalá de Henares, 28805 Madrid, Spain; josealberto.garcia@salud.madrid.org
6 Department of Medicine, University of Alcalá, Alcalá de Henares, 28805 Madrid, Spain
7 Spanish Center for Pharmacoepidemiologic Research (CEIFE), 28004 Madrid, Spain; lagarcia@ceife.es

* Correspondence: francisco.abajo@uah.es; Tel.: +34-91-885-25-93
† These authors contributed equally to the study.

Received: 24 November 2019; Accepted: 3 December 2019; Published: 5 December 2019

Abstract: Objectives: To test the hypothesis that allopurinol reduces the risk of acute myocardial infarction (AMI) in hyperuricemic patients and to assess whether the effect is dependent on dose, duration and serum uric acid (SUA) level attained after treatment. Methods: Nested case-control study over the period 2002–2015. From a cohort of patients aged 40–99 years old, we identified incident AMI cases and randomly selected five controls per case, matched for exact age, sex and index date. Adjusted odds ratios (AOR) and 95% CI were computed through unconditional logistic regression. Only new users of allopurinol were considered. Results: A total of 4697 AMI cases and 18,919 controls were included. Allopurinol use was associated with a reduced risk of AMI mainly driven by duration of treatment (AOR ≥180 days = 0.71; 95% CI: 0.60–0.84). Among long-term users (≥180 days), the reduced risk was only observed when the SUA level attained was below 7 mg/dL (AOR <6 mg/dL = 0.64; 95% CI: 0.49–0.82; AOR 6–7 mg/dL = 0.64; 95% CI: 0.48–0.84; AOR >7 mg/dL = 1.04; 95% CI: 0.75–1.46; p for trend = 0.001). A dose-effect was observed but faded out once adjusted for the SUA level attained. The reduced risk of AMI occurred in both patients with gout and patients with asymptomatic hyperuricemia. Conclusions: The results confirm a cardioprotective effect of allopurinol which is strongly dependent on duration and SUA level attained after treatment.

Keywords: allopurinol; serum uric acid levels; acute myocardial infarction; hyperuricemia; gout

1. Introduction

Mounting evidence shows that hyperuricemia and gout are associated with an increased risk of cardiovascular disease [1–4], suggesting that they are important risk factors, though a reverse causality
cannot be ruled out [5]. In this context, it is of interest to know whether urate-lowering therapy (ULT) reduces the risk of cardiovascular events in hyperuricemic patients. Allopurinol, a xanthine oxidase inhibitor (XOI), is the first-line ULT for patients with gout to prevent acute flares [6,7]. Often, it is also used to treat asymptomatic hyperuricemia, though this practice is generally not supported [8,9]. In the last few years, many studies have provided evidence on the cardiovascular benefits of allopurinol [5,10]. In 2015, our group reported a risk reduction of acute myocardial infarction (AMI), which was dose- and duration-dependent, among allopurinol initiators [11], but recent studies yielded conflicting results, with some reporting a protective effect [12–15] and others no effect [16–18] or an increased risk [19]. Thus, the subject is still a matter of controversy and further studies are needed [1,2].

Another important issue still unsolved is whether the potential protective effect of allopurinol on AMI is related or not with the lowering of serum uric acid (SUA) levels [1,2,20]. Previous studies either did not address the issue [12,14] or did not find a relation [11,13,15,16], although the sample size could have been a limitation to draw a firm conclusion.

In the present study, performed in hyperuricemic patients with or without gout, we aimed to confirm the protective effect of allopurinol on AMI and to assess the role of daily dose, duration of treatment and SUA level attained after treatment.

2. Patients and Methods

2.1. Data source and Study Design

We conducted a case-control study nested in a primary cohort selected from BIFAP (a Spanish primary healthcare database; see Appendix A for details) [21] over the study period 1 January 2002 to 31 December 2015. The primary cohort was composed of patients aged 40 to 99 years old, registered with their primary care physician (PCP) for at least 1 year and who did not have a previous record of cancer or AMI. The first day the patients met all the criteria mentioned above was the “start date” of the follow-up. The primary cohort was composed of 3,764,470 subjects. They were then followed until the first of the following events: an incident AMI, 100 years old, a record of cancer, death, or the end of the study period.

2.2. Selection of Cases and Controls

Incident AMI cases were initially searched through both codes and text on diagnosis fields and validated through manual review of clinical records (see Appendix B for details). The “index date” was considered the date of the first record of AMI. Five controls per case were randomly selected from the underlying cohort following a risk set sampling in which controls were individually matched to cases by exact age, sex, and index date.

2.3. Definitions of Gout and Asymptomatic Hyperuricemia

Once cases and controls were selected, we identified those having gout or asymptomatic hyperuricemia. A patient was considered to have “gout” when his/her automated clinical record had a specific code of gout or related terms within the diagnosis field (“gout”, “tophus”, “gouty arthritis” or “podagra”). A patient was considered to have “asymptomatic hyperuricemia” when, having no record of gout, he/she had one of the following criteria (in descending order): (1) a text of “hyperuricemia” within the diagnosis field; (2) at least one SUA level prior to the index date above 8 mg/dL (480 µm/L) in men or 7 mg/dL (420 µm/L) in women; (3) at least two SUA levels prior to the index date between 7 and 8 mg/dL in men or between 6 and 7 mg/dL in women. Patients with an isolated diagnosis of uric renal lithiasis were not considered.

2.4. New Users Design

The analysis was performed among new-users of allopurinol. For that purpose, we excluded all cases and controls with a recorded prescription of allopurinol before the start date [22] (Figure 1).
were on daily doses over 300 mg). Duration of treatment was computed summing up consecutive
prescriptions (with a maximum gap of 90 days between the end of one and the starting of the next),
and then grouped in two categories: less than 180 days and 180 days or longer.

2.7. Potential Confounding Factors

The following comorbidities (recorded before the index date) were assessed as potential
confounding factors: cerebrovascular disease (ischemic, hemorrhagic or non-specified stroke and
transient ischemic attack), heart failure, angina pectoris (recorded as such and/or use of nitrates),
peripheral artery disease (PAD), hypertension, diabetes (recorded as such and/or use of glucose-lowering
drugs), dyslipidemia (recorded as such and/or use of lipid-lowering drugs), rheumatoid arthritis,
osteoarthritis, and chronic kidney disease. In addition, we considered the following factors: number of visits to the PCPs in the year prior to the index date, body mass index (BMI), smoking, and current use of the following drugs: low-dose aspirin, non-aspirin antiplatelet drugs, oral anticoagulants, non-steroidal anti-inflammatory drugs (NSAIDs), colchicine, corticosteroids, angiotensin-converting enzyme inhibitors (ACEI), angiotensin II receptor blockers (ARB), calcium-channel blockers, beta-blockers, alfa-blockers, and diuretics.

2.8. Statistical Analysis

The association between incident AMI and the exposure to the drugs of interest was evaluated by computing the Odds Ratio (OR) and the corresponding 95% confidence intervals (CI) through unconditional logistic regression models. First, we estimated the crude ORs including only the exposure and the matching variables (age, sex and calendar year); then, we computed the adjusted OR (AOR) adding all the potential confounding factors mentioned in the previous section. Furthermore, we studied the interaction with age (stratified as less than 65 and equal or greater than 65 years old), sex, obesity (defined as a BMI over 30 kg/m²), history of diabetes, history of atherothrombotic disease (includes angina pectoris, PAD or cerebrovascular accident), and concomitant use of statins (all of them patients with dyslipidemia) or drugs inhibiting the renin-angiotensin system (either ACEI or ARB). For the statistical evaluation of the interaction, we ran adjusted models across different categories of the interacting variables and computed the AORs associated with current use of the drugs of interest as compared to non-use in each stratum. The AORs across strata were compared using the test of interaction described by Altman and Bland [23]. Results were considered statistically significant when the p-value was lower than 0.05.

Missing values for smoking (34.7%), BMI (20.1%) and SUA level (12.1%) were addressed performing multiple imputations by chained equation (MICE) models [24] (see Appendix C for details).

We conducted all analyses using STATA version 15/SE (StataCorp. College Station, TX, USA).

2.9. Sensitivity Analyses

Two sensitivity analyses were performed: (1) using only patients with complete data of SUA levels; and (2) excluding hypertension from the model, as it may be acting as an intermediate variable in the causal pathway between gout/hyperuricemia and AMI [25].

2.10. Ethics Review

Access to anonymized data from BIFAP was granted by the BIFAP Scientific Committee (project #04/2016; approval date: 26 May 2016). According to the Spanish law, no specific ethical review was required for studies using fully anonymized data.

3. Results

We included a total of 4697 incident AMI cases and 18,919 controls, all of them with a record of either gout or asymptomatic hyperuricemia (Figure 1). Their characteristics are outlined in Table 1. As expected, the prevalence of cardiovascular risk factors and use of cardiovascular drugs was higher in cases as compared to controls.
Table 1. Characteristics of cases and controls. All patients were hyperuricemic. Prevalent users of allopurinol were excluded.

|                         | Cases     | Controls   | Crude OR * (95% CI) | Adjuster OR ‡ (95% CI) |
|-------------------------|-----------|------------|---------------------|-----------------------|
| **Age, mean (SD)**      | 70.0 (±12.9) | 69.9 (±12.6) | -                   | -                     |
| **Men**                 | 3199 (68.1) | 13503 (71.4) | -                   | -                     |
| **Visits (last 12 months)** |           |            |                     |                       |
| Up to 5                 | 682 (14.5)  | 3819 (20.2)  | 1 (ref.)            | 1 (ref.)              |
| 6–15                    | 1883 (40.1)| 8127 (43.0)  | 1.35 (1.22–1.49)    | 1.21 (1.09–1.34)      |
| 16–24                   | 1097 (23.4)| 3892 (20.6)  | 1.69 (1.51–1.89)    | 1.41 (1.25–1.60)      |
| ≥25                     | 1035 (22.0)| 3081 (16.3)  | 2.06 (1.83–2.31)    | 1.58 (1.39–1.81)      |
| **BMI kg/m²**           |           |            |                     |                       |
| Up to 24.9              | 434 (9.2)  | 1765 (9.3)  | 1 (ref.)            | 1 (ref.)              |
| 25–29                   | 2158 (45.9)| 9097 (48.1)  | 0.98 (0.87–1.10)    | 1.01 (0.90–1.14)      |
| 30–34                   | 1606 (34.2)| 6261 (33.1)  | 1.05 (0.93–1.18)    | 1.04 (0.92–1.18)      |
| 35–49                   | 376 (8.0)  | 1413 (7.5)   | 1.06 (0.91–1.24)    | 0.96 (0.82–1.13)      |
| ≥40                     | 123 (2.6)  | 383 (2.0)    | 1.26 (1.00–1.58)    | 1.10 (0.86–1.39)      |
| **Smoking**             |           |            |                     |                       |
| Never smoking           | 1499 (31.9)| 6792 (35.9)  | 1 (Ref.)            | 1 (Ref.)              |
| Current smoker          | 1281 (27.3)| 3637 (19.2)  | 1.45 (1.33–1.58)    | 1.43 (1.31–1.57)      |
| Past smoker             | 394 (8.4)  | 1815 (9.6)   | 1.03 (0.91–1.17)    | 0.98 (0.86–1.11)      |
| Unknown                 | 1523 (32.4)| 6675 (35.3)  | Imputed            | Imputed              |
| **CVA**                 |           |            |                     |                       |
| Ischemic                | 163 (3.5)  | 474 (2.5)    | 1.42 (1.19–1.71)    | 1.06 (0.87–1.29)      |
| Hemorrhagic             | 17 (0.36)  | 68 (0.36)    | 1.03 (0.61–1.76)    | 0.89 (0.52–1.54)      |
| Unspecified             | 112 (2.4)  | 404 (2.1)    | 1.16 (0.93–1.43)    | 0.89 (0.71–1.11)      |
| TIA                     | 150 (3.2)  | 495 (2.6)    | 1.25 (1.03–1.50)    | 1.03 (0.84–1.25)      |
| Heart failure           | 338 (7.2)  | 957 (5.1)    | 1.45 (1.27–1.66)    | 1.22 (1.06–1.41)      |
| **Angina pectoris** §   | 660 (14.1) | 1293 (6.8)   | 2.28 (2.06–2.52)    | 1.69 (1.51–1.90)      |
| **PAD**                 | 301 (6.4)  | 611 (3.2)    | 2.16 (1.87–2.50)    | 1.54 (1.32–1.79)      |
| **Hypertension**        | 3444 (73.3)| 13007 (68.8)| 1.25 (1.16–1.35)    | 1.06 (0.97–1.17)      |
| Diabetes §              | 1669 (35.5)| 4781 (25.3)  | 1.63 (1.52–1.75)    | 1.37 (1.27–1.47)      |
| Dyslipidemia **         | 2847 (60.6)| 9919 (52.4)  | 1.39 (1.30–1.49)    | 1.12 (1.04–1.20)      |
| Rheumatoid arthritis    | 39 (0.83)  | 128 (0.68)   | 1.20 (0.84–1.72)    | 1.00 (1.69–1.46)      |
| Osteoarthritis          | 601 (12.8) | 2298 (12.2)  | 1.04 (0.94–1.14)    | 1.02 (0.92–1.13)      |
| Chronic kidney failure  | 441 (9.4)  | 1389 (7.3)   | 1.32 (1.17–1.48)    | 1.08 (0.96–1.22)      |
| Current use of Low-dose aspirin | 969 (20.6)| 2826 (14.9)  | 1.63 (1.49–1.77)    | 1.13 (1.03–1.25)      |
| Other antiplatelet drugs| 323 (6.9)  | 624 (3.3)    | 2.27 (1.97–2.61)    | 1.50 (1.28–1.76)      |
| Oral anticoagulants     | 316 (6.7)  | 1405 (7.4)   | 0.90 (0.79–1.02)    | 0.70 (0.60–0.81)      |
| NSAIDs                  | 501 (10.7) | 2005 (10.6)  | 1.04 (0.93–1.17)    | 0.94 (0.84–1.07)      |
| Colchicine              | 67 (1.43)  | 220 (1.16)   | 1.28 (0.97–1.68)    | 1.22 (0.92–1.63)      |
| Corticosteroids         | 124 (2.6)  | 333 (1.8)    | 1.55 (1.26–1.91)    | 1.38 (1.11–1.72)      |
| ACE inhibitors          | 1187 (25.3)| 4532 (24.0)  | 1.16 (1.07–1.25)    | 0.93 (0.85–1.02)      |
| ARB                     | 1089 (23.2)| 3999 (21.1)  | 1.18 (1.09–1.28)    | 0.93 (0.85–1.03)      |
| CCB                     | 975 (20.8) | 2963 (15.7)  | 1.51 (1.38–1.64)    | 1.23 (1.12–1.35)      |
| Beta-Blockers           | 697 (14.8) | 2136 (11.3)  | 1.41 (1.28–1.55)    | 1.09 (0.98–1.21)      |
| Alfa-Blockers           | 183 (3.9)  | 706 (3.7)    | 1.08 (0.91–1.27)    | 0.85 (0.71–1.01)      |
| Diuretics               | 1112 (23.7)| 3957 (20.8)  | 1.23 (1.13–1.34)    | 1.00 (0.91–1.10)      |

Abbreviations: OR: Odds Ratio, SD: Standard Deviation, CI: Confident Interval. CVA: Cerebrovascular Accident, TIA: Transient Ischemic Accident, PAD: Peripheral Artery Disease, COPD: Chronic Obstructive Pulmonary Disease, BMI: Body Mass Index, NSAIDs: Non-steroidal Anti-inflammatory Drugs, ACE: Angiotensin Converting Enzyme. ARB: Angiotensin II-Receptor Blockers; CCB: Calcium-channel blockers. * Adjusted only for the matching factors (age, sex and calendar year). ‡ Adjusted for the matching factors (age, sex and calendar year) and all covariables included in the table. § Recorded as such or when patients were using nitrates. † Recorded as such or when patients were using glucose-lowering drugs. ** Recorded as such or when patients were using lipid-lowering drugs.
3.1. Allopurinol Use and Risk of AMI and Effect of Dose and Duration

Current use of allopurinol was slightly lower among cases (321; 6.8%) than in controls (1417; 7.5%), leading to a crude OR of 0.93 (0.82–1.05). After full adjustment, the AOR went down to 0.84 (95% CI: 0.73–0.96) and decreased even further at a dose of 300 mg or higher (AOR = 0.75; 95% CI: 0.60–0.93), after durations of 180 days or longer (AOR = 0.71; 95% CI: 0.60–0.84) (test for trend, \(p = 0.0001\)) and, particularly, when these two conditions were met (AOR = 0.61; 95% CI: 0.46–0.81). The strongest reduction of AMI risk was observed when patients used high doses for 2 years or longer (AOR = 0.48; 95% CI: 0.31–0.75). A reduction of risk was still observed with low daily doses of allopurinol when they used it long-term (AOR = 0.77; 95% CI: 0.63–0.94) (Table 2).

Table 2. Risk of AMI among new users of allopurinol according to recency of use, daily dose and duration of treatment.

| Recency   | Cases (%) | Controls (%) | Crude OR † (95% CI) | Adjusted OR ‡ (95% CI) |
|-----------|-----------|--------------|----------------------|------------------------|
| Non-use   | 4060 (86.4) | 16127 (85.2) | 1 (Ref.)             | 1 (Ref.)               |
| Current   | 321 (6.8)  | 1417 (7.5)   | 0.93 (0.82–1.05)     | 0.84 (0.73–0.96)       |
| Recent    | 144 (3.1)  | 619 (3.3)    | 0.95 (0.79–1.14)     | 0.89 (0.73–1.08)       |
| Past      | 172 (3.7)  | 756 (4.0)    | 0.93 (0.78–1.10)     | 0.89 (0.75–1.07)       |

| Daily dose * | Cases (%) | Controls (%) | Crude OR † (95% CI) | Adjusted OR ‡ (95% CI) |
|--------------|-----------|--------------|----------------------|------------------------|
| <300 mg      | 213 (4.5)  | 883 (4.7)    | 0.98 (0.84–1.15)     | 0.90 (0.76–1.05)       |
| ≥300 mg      | 108 (2.3)  | 534 (2.8)    | 0.83 (0.68–1.03)     | 0.75 (0.60–0.93)       |

| Duration *   | Cases (%) | Controls (%) | Crude OR † (95% CI) | Adjusted OR ‡ (95% CI) |
|--------------|-----------|--------------|----------------------|------------------------|
| <180 days    | 129 (2.8)  | 449 (2.4)    | 1.17 (0.96–1.43)     | 1.13 (0.91–1.39)       |
| ≥180 days    | 192 (4.1)  | 968 (5.1)    | 0.81 (0.69–0.95)     | 0.71 (0.60–0.84)       |
| 180–729 days | 116 (2.5)  | 537 (2.8)    | 0.88 (0.72–1.08)     | 0.76 (0.61–0.94)       |
| >729 days    | 76 (1.62)  | 431 (2.3)    | 0.72 (0.57–0.93)     | 0.64 (0.50–0.83)       |

\(p\) for trend = 0.0001

* Among current users. † Odds Ratio (OR) Adjusted only for matching factors (age, sex and calendar year). ‡ Odds Ratio (OR) Adjusted for covariates shown in Table 1. Note: Percentages equal to or greater than 2 have been rounded to the first decimal place. Odds ratios and percentages less than 2 have been rounded to the second decimal.

3.2. Allopurinol Use and Risk of AMI According to SUA Levels Attained

We found a statistically significant reduced risk of AMI when the SUA level was below 6 mg/dL (AOR = 0.77; 95% CI: 0.63–0.96) (Figure 2). At durations longer than 180 days, a reduced risk was observed when the SUA level was either less than 6 mg/dL (AOR = 0.64; 95% CI: 0.49–0.82) or between 6 and 7 mg/dL (AOR = 0.64; 95% CI: 0.48–0.84), but not when the SUA level was higher than 7 mg/dL (AOR = 1.04; 95%: 0.75–1.46) (test for trend, \(p = 0.0001\)) (Figure 2). Daily dose barely modulated the AORs associated with allopurinol within the different SUA level categories (Figure 2).
Among asymptomatic hyperuricemic patients, the effect of allopurinol appeared to be weaker, but used at high doses (AOR = 0.66; 95% CI: 0.48–0.90) or for long-term periods (AOR = 0.68; 95% CI: 0.33–0.73). In long-term users, a trend with SUA level was observed (p = 0.001) (Figure 3). Among asymptomatic hyperuricemic patients, the effect of allopurinol appeared to be weaker, but reached statistical significance when used for periods of 180 days or longer (AOR = 0.75; 0.59–0.94) (test for trend, p = 0.010), and particularly when long durations were associated with SUA levels below 7 mg/dL (AOR < 6 mg/dL = 0.66; 0.46–0.95; AOR 6-7 mg/dL = 0.63; 0.43–0.94; AOR > 7 mg/dL = 1.31; 0.81–2.13; p for trend = 0.001) (Figure 4).

### 3.3. Allopurinol Use and AMI Stratified by Gout and Asymptomatic Hyperuricemia

In gout patients, the current use of allopurinol was associated with a decreased risk of AMI when used at high doses (AOR = 0.66; 95% CI: 0.48–0.90) or for long-term periods (AOR = 0.68; 95% CI: 0.53–0.89) (test for trend, p = 0.004), and, particularly, when patients met both features (AOR = 0.49; 95% CI: 0.33–0.73). In long-term users, a trend with SUA level was observed (p = 0.001) (Figure 3). Among asymptomatic hyperuricemic patients, the effect of allopurinol appeared to be weaker, but reached statistical significance when used for periods of 180 days or longer (AOR = 0.75; 0.59–0.94) (test for trend, p = 0.010), and particularly when long durations were associated with SUA levels below 7 mg/dL (AOR < 6 mg/dL = 0.66; 0.46–0.95; AOR 6-7 mg/dL = 0.63; 0.43–0.94; AOR > 7 mg/dL = 1.31; 0.81–2.13; p for trend = 0.001) (Figure 4).

### Figure 2. Risk of acute myocardial infarction among current users of allopurinol by serum uric acid (SUA) level in different scenarios. Long-term use is defined as a duration of 180 days or longer. AOR: Adjusted Odds Ratio, 300+ mg means 300 mg or higher.

| SUA level | Cases (%) | Controls (%) | AOR (95% CI) |
|-----------|-----------|--------------|--------------|
| <6.0 mg/dL| 118 (2.5) | 572 (3.0)    | 0.77 (0.63–0.96) |
| 6.0–7.0 mg/dL| 129 (2.8) | 591 (3.1)    | 0.81 (0.66–1.00) |
| ≥7.0 mg/dL| 74 (1.58) | 253 (1.34)   | 1.04 (0.79–1.37) |

| SUA level among long term users | Cases (%) | Controls (%) | AOR (95% CI) |
|---------------------------------|-----------|--------------|--------------|
| <6.0 mg/dL                      | 77 (1.84) | 437 (2.3)    | 0.64 (0.49–0.82) |
| 6.0–7.0 mg/dL                   | 66 (1.38) | 367 (1.94)   | 0.84 (0.48–0.84) |
| ≥7.0 mg/dL                      | 50 (1.06) | 164 (0.87)   | 1.04 (0.75–1.48) |

| SUA level among long term users by daily dose | Cases (%) | Controls (%) | AOR (95% CI) |
|-----------------------------------------------|-----------|--------------|--------------|
| <6.0 mg/dL <300 mg                            | 40 (0.85) | 228 (1.21)   | 0.64 (0.45–0.91) |
| ≥300 mg                                        | 37 (0.79) | 209 (1.09)   | 0.65 (0.38–0.97) |
| 6.0–7.0 mg/dL 300–399 mg                      | 48 (0.85) | 246 (1.36)   | 0.69 (0.50–0.95) |
| ≥400 mg                                        | 17 (0.36) | 121 (0.64)   | 0.52 (0.31–0.88) |
| ≥7.0 mg/dL 7 mg/dL – 1 mg/dL                  | 40 (0.85) | 116 (0.61)   | 1.17 (0.80–1.61) |
| ≥1 mg/dL                                       | 10 (0.21) | 49 (0.25)    | 0.73 (0.36–1.47) |

### Figure 3. Patients with gout only. Risk of AMI among new users of allopurinol according to recency of use, daily dose, duration of treatment, and SUA level reached after treatment. AOR: Adjusted Odds Ratio, 300+ mg means 300 mg or higher, 180+ days means 180 days or longer.

| Recency | Non-use | Current | Recent | Past | AOR (95% CI) |
|---------|---------|---------|--------|------|--------------|
|         | 462 (54.9) | 2017 (58.9) | 0.83 (0.61–1.03) |
|         | 161 (20.5) | 745 (21.8) |
|         | 66 (8.0) | 306 (8.6) |
|         | 93 (11.9) | 356 (10.4) |

| Daily dose* | Cases (%) | Controls (%) | AOR (95% CI) |
|-------------|-----------|--------------|--------------|
| <300 mg     | 102 (13.0) | 410 (12.3)   | 0.87 (0.75–1.02) |
| ≥300 mg     | 55 (7.5) | 338 (9.8)    | 0.66 (0.48–0.90) |

| Duration* | Cases (%) | Controls (%) | AOR (95% CI) |
|-----------|-----------|--------------|--------------|
| <180 days | 63 (8.0) | 213 (6.2) | 0.90 (0.75–1.06) |
| ≥180 days | 129 (15.9) | 532 (15.9) |

| Daily dose & duration* | Cases (%) | Controls (%) | AOR (95% CI) |
|------------------------|-----------|--------------|--------------|
| <300 mg & <180 days   | 38 (4.8) | 131 (3.8) | 0.80 (0.61–1.07) |
| 300+ mg & <180 days   | 64 (8.2) | 276 (8.2) | 0.85 (0.63–1.15) |
| ≥300 mg & ≥180 days   | 25 (3.2) | 62 (2.4) | 1.19 (0.73–1.92) |
| 300+ mg & ≥180 days   | 44 (5.3) | 253 (7.4) | 0.49 (0.33–0.73) |

| SUA level (long-term users)* | Cases (%) | Controls (%) | AOR (95% CI) |
|-----------------------------|-----------|--------------|--------------|
| <6 mg/dL                    | 26 (4.8) | 246 (7.2) | 0.61 (0.42–0.90) |
| 6-7 mg/dL                   | 34 (4.3) | 187 (5.5) | 0.66 (0.44–0.99) |
| ≥7 mg/dL                    | 26 (3.3) | 55 (2.9) | 0.69 (0.51–1.04) |

*) Among current users
Figure 4. Patients with asymptomatic hyperuricemia. Risk of AMI among new users of allopurinol according to recency of use, daily dose, duration of treatment, and serum uric acid (SUA) level attained after treatment. AOR: Adjusted Odds Ratio, 300+ mg means 300 mg or higher, 180+ days means 180 days or longer.

3.4. Allopurinol Use and Risk of AMI in Different Subgroups

The results of the potential interaction of allopurinol use with sex, age, obesity, antecedents of atherothrombotic disease, diabetes, and concurrent use of statins or drugs blocking the renin-angiotensin system are shown in Figure 5. No evidence of a statistical interaction was found with any of them.

Figure 5. Assessment of interaction between long-term current use of allopurinol and different factors. Long-term use is defined as a duration of 180 days or longer. AOR: Adjusted Odds Ratio, BMI: Body mass index, Age 65+ means 65 years or older, BMI 30+ means 30 Kg/m² or higher.
3.5. Sensitivity Analyses

(1) In patients with complete SUA data, we also found a reduced risk of AMI associated with lower SUA levels among allopurinol current users (AOR < 6 mg/dL = 0.70; 95% CI: 0.53–0.91; AOR 6–7 mg/dL = 0.88; 95%CI:0.63–1.24; AOR > 7 mg/dL = 1.03; 95%CI:0.76–1.40) showing a significant trend (p = 0.011) (Table 3); (2) the exclusion of hypertension from the adjusted model had no impact in the AOR estimates.

| SUA Level | Cases (%) | Controls (%) | Crude OR † | Adjusted OR ‡ |
|-----------|-----------|--------------|------------|---------------|
| <6 mg/dL  | 70 (1.68) | 381 (2.3)    | 0.74 (0.57–0.96) | 0.70 (0.53–0.91) |
| 6–7 mg/dL | 45 (1.08) | 201 (1.21)   | 0.91 (0.66–1.26) | 0.88 (0.63–1.24) |
| >7 mg/dL  | 61 (1.46) | 220 (1.33)   | 1.12 (0.85–1.50) | 1.03 (0.76–1.40) |

*p for trend = 0.011

| SUA level among long-term users * |
|----------------------------------|
| <6 mg/dL                         |
| 61 (1.46)                       |
| 334 (2.0)                       |
| 0.74 (0.56–0.98)               |
| 0.69 (0.51–0.92)               |
| 6–7 mg/dL                       |
| 35 (0.84)                       |
| 172 (1.04)                      |
| 0.83 (0.57–1.19)               |
| 0.79 (0.54–1.15)               |
| >7 mg/dL                        |
| 46 (1.10)                       |
| 148 (0.89)                      |
| 1.26 (0.90–1.76)               |
| 1.11 (0.78–1.58)               |

*p for trend = 0.007

| SUA level among long-term users by daily dose * |
|-----------------------------------------------|
| <6 mg/dL by daily dose                         |
| <300 mg                                       |
| 30 (0.72)                                     |
| 159 (0.96)                                    |
| 0.76 (0.51–1.12)                             |
| 0.69 (0.46–1.04)                             |
| ≥300 mg                                       |
| 31 (0.74)                                     |
| 175 (1.05)                                    |
| 0.72 (0.49–1.06)                             |
| 0.68 (0.45–1.01)                             |
| 6–7 mg/dL by daily dose                       |
| <300 mg                                       |
| 28 (0.67)                                     |
| 130 (0.78)                                    |
| 0.87 (0.58–1.32)                             |
| 0.83 (0.54–1.26)                             |
| ≥300 mg                                       |
| 7 (0.17)                                      |
| 42 (0.25)                                     |
| 0.68 (0.31–1.52)                             |
| 0.66 (0.29–1.51)                             |
| >7 mg/dL by daily dose                        |
| <300 mg                                       |
| 38 (0.91)                                     |
| 103 (0.62)                                    |
| 1.50 (1.03–2.18)                             |
| 1.31 (0.88–1.93)                             |
| ≥300 mg                                       |
| 8 (0.19)                                      |
| 45 (0.27)                                     |
| 0.72 (0.34–1.53)                             |
| 0.65 (0.30–1.42)                             |

* Among current users. † Adjusted Odds Ratio (OR) only for matching factors (age, sex and calendar year). ‡ Adjusted Odds Ratio (OR) for covariates shown in Table 1. Note: Percentages equal to or greater than 2 have been rounded to the first decimal place. Odds ratios and percentages less than 2 have been rounded to the second decimal. Long-term means 180 days or longer.

4. Discussion

In the present study, we found that the use of allopurinol was associated with a reduction of AMI risk, which was mainly observed when the duration of treatment was 180 days or longer and when the SUA level attained after treatment was below 7 mg/dL. A significant dose effect was also observed but proved less relevant once results were adjusted for the SUA level. Such cardioprotective effect of allopurinol was found in both gout and asymptomatic hyperuricemic patients.

The present study confirms the results we previously reported on allopurinol and AMI risk [11], but with more robust data. So far, other three observational studies performed in different countries (France [12], Denmark [13] and the US [14]), with different populations (either general population [12], hyperuricemic subjects [13], and patients with gout and diabetes [14]) and using different designs (case-control [12] and cohort [13,14] studies) have consistently reported a protective effect of allopurinol on atherothrombotic events (AMI alone [12], AMI or stroke [14], AMI or stroke or cardiovascular death [13]) ranging from 11% [13] to 33% [14]. Also, Wei et al. [26], comparing high doses with low doses of allopurinol, found a hazard ratio of 0.69 (95% CI: 0.50–0.94) for cardiovascular events in the UK. Finally, Bredemeier et al. [27], in a meta-analysis of randomized clinical trials, estimated a
relative risk of AMI of 0.38 (95% CI: 0.17–0.83) among allopurinol users as compared to placebo or no treatment. Other authors [16–18], however, did not find a reduced risk, although the very low doses used by patients [18] and the low adherence to treatment observed [17] could partly explain some of the discrepant results.

The main novelty of the present study is the close relation found between AMI risk and SUA level reached after allopurinol treatment. Among long-term users, the reduced risk was around 40% when SUA level was below 7 mg/dL, while no benefit was observed when SUA level was over 7 mg/dL. These results are apparently in contrast with those by Desai et al. [28], who did not find a decreased risk of cardiovascular events with a reduction of >3 mg/dL in SUA levels. Nevertheless, they did not evaluate specifically the effect of allopurinol (actually, around 40% patients were not on ULT) and, hence, results are not comparable. Furthermore, the intensity of reduction may be less important than reaching a SUA level below a certain threshold. It is interesting to note that 7 mg/dL is close to the accepted solubility threshold of uric acid (6.8 mg/dL or 404.5 µmol/L) [20] and our data suggest that this level may be critical to obtain cardiovascular benefits. Recently, Pérez-Ruiz et al. [29] reported an increased risk of all-cause death and cardiovascular death in gout patients who failed to reach a target SUA level <360 µmol/L (6 mg/dL).

The underlying biological mechanism for allopurinol cardioprotection is unknown, although most hypotheses link the benefits of allopurinol with the inhibition of xanthine oxidase and the resulting reduction of reactive oxygen species (ROS) [30]. In a series of elegant clinical studies, Struthers et al. [31,32] provided compelling evidence of a remarkable effect of allopurinol on oxidative stress when used at very high doses (600 mg), which resulted in an improvement of the endothelial dysfunction. Our data show that the cardioprotective effect of allopurinol is stronger at higher doses which is compatible with this hypothesis, although such dose-relation tends to fade out when results are adjusted for the SUA level attained. However, it is important to note that in our study, only three patients used allopurinol at doses higher than 300 mg which might have prevented us from observing a relevant direct effect independent from the SUA level attained. The data show that the cardioprotective effect of allopurinol improves as duration of treatment increases, which is consistent with results from other studies [11,12]. Both the inflammatory state induced by urate deposits [33] (and maybe soluble uric acid itself [34]), and the atherosclerotic process caused by endothelial dysfunction and other cardiovascular risk factors associated with gout/hyperuricemia [20,33], require time to be reversed and this could be the biological explanation for the time-dependent effect of allopurinol. Additionally, the start of treatment with ULT mobilizes the urate deposits which could increase the pro-inflammatory state and, in turn, the cardiovascular risk, a factor which may counteract any potential short-term protective effect of allopurinol.

Taking all these data together, we postulate that the protective effect of allopurinol on AMI may have a double component: a direct effect on ROS only observable with high daily doses (300 mg or higher); and a SUA-dependent component, clearly evident when serum concentrations are maintained below 7 mg/dL. Nevertheless, both mechanisms are closely linked as SUA level reduction is also a marker of the inhibition of XO activity. The present study only focused on AMI, but it is expected that a similar effect could be observed on other atherothrombotic events like ischemic stroke.

The reduced risk of AMI with allopurinol use was particularly observed in patients with gout, but it is noteworthy that we also observed a protective effect in patients with asymptomatic hyperuricemia provided that treatment was prolonged and SUA levels maintained below 7 mg/dL. Whether the protective effect observed in these patients should change the general recommendation of not using allopurinol in them [6–9], is a question beyond the scope of the present research and should be addressed in specific studies considering the risks of allopurinol, in particular severe cutaneous reactions [35–38].
We did not find a statistically significant interaction between allopurinol use and any of the variables examined, and we must conclude that allopurinol elicits similar benefits in all subgroups studied. In the case of use of statins or ACEI/ARB, it means that the benefits of allopurinol are added to the cardiovascular benefits of these drugs. A lower relative effect was found in the subgroups with the highest cardiovascular risk, but this is an expected result as the same absolute risk reduction translates into lower and lower relative risks when the background risk increases.

In our study population of gout patients, the risk of AMI was roughly estimated in two per 1000 person-years. Assuming that the use of allopurinol was associated with a long-term risk reduction of around 40% (when SUA level is below 7 mg/dL), the risk of AMI among exposed would be 1.2 per 1000 person-years, leading to an absolute risk reduction (ARR) of 0.8 per 1000 person-years and a Number Needed to Treat (NNT = 1/ARR) of 1250 persons per year. In other words, for every set of 1250 patients treated with allopurinol per year, one patient would be saved from having an AMI attributable to this drug.

Our study has a number of strengths: (1) researchers who performed the case validation were blinded to drug exposure which prevents a differential misclassification of the disease conditioned by the exposure; (2) controls were randomly extracted from the underlying cohort, assuring that they represented the exposure of the population that gave rise to cases and thereby avoiding a selection bias [39]; (3) all patients were hyperuricemic which makes the groups more comparable in terms of background cardiovascular risk than those studies performed in the general population; (4) only new users of allopurinol were considered, which prevents from bias linked to early events [22]; and (5) the sensitivity analyses did not materially change the results, showing that they are robust.

The main limitations of the study are as follows: (1) It is an observational study, so residual confounding due to unknown or unmeasured factors is still possible; (2) SUA levels were not available in 12.1% of patients; however, we applied a multiple imputation method which is recognized as the best method to address missing data [40]; on the other hand, the sensitivity analysis including only patients with complete data showed consistent results, though less precise; (3) physicians fill prescriptions through the computer, so a misclassification of the exposure for not recording prescription-only drugs is unlikely, but the adherence to treatment by patients cannot be assured; nevertheless, the impact of this potential error would have operated against the working hypothesis; (4) the primary care physicians do not record reliable information on diet and other lifestyle factors and the effect of a modification of these factors on SUA levels could not be assessed; however, guidelines agree on stating that these interventions have little effect on urate concentrations [6] and thus the impact of this missing information is probably small; and (5) the exposure to other ULT drugs different from allopurinol was very small to perform a meaningful analysis with them (febuxostat and benzbromarone, the only ULT drugs available in Spain during the study period, had a very limited use: only 14 cases and 34 controls were current users of febuxostat; and no cases and only three controls were current users of benzbromarone).

5. Conclusions

The results of the present study show a protective effect of allopurinol on AMI risk, which is strongly dependent on the duration and SUA level attained after treatment. The greatest protective effect is observed when the duration of treatment is 6 months or longer and SUA level is below 7 mg/dL. Once these conditions are met, the daily dose (up to 300 mg) seems to play a minor role. The cardiovascular benefits of allopurinol should be an extra incentive for physicians and patients to be fully adherent to ULT in the long-lasting treatment of gout, in addition to the prevention of acute flares. Although our data suggests that asymptomatic hyperuricemic patients might also gain cardiovascular benefits with allopurinol, the benefit–risk ratio in this population should be further evaluated in specific studies.
Author Contributions: Conceptualization, F.J.D.A. and S.R.-M.; methodology, F.J.D.A., S.R.-M., M.G., A.G.-L., and A.R.-M.; software, M.G., and S.R.-M.; validation, S.R.-M., M.G., D.G.-B., D.B.-H., A.G.-L., and F.J.D.A.; formal analysis, S.R.-M., and F.J.D.A.; investigation, F.J.D.A., S.R.-M., M.G., A.G.-L., R.M., L.A.G.-R., A.R.-M., D.G.-B., and D.B.-H.; resources, F.J.D.A., M.G., and A.G.-L.; data curation, S.R.-M., and M.G.; writing—original draft preparation, S.R.-M., and F.J.D.A.; writing—review and editing, F.J.D.A., S.R.-M., M.G., A.G.-L., R.M., L.A.G.-R., A.R.-M., D.G.-B., and D.B.-H.; visualization, S.R.-M.; supervision, F.J.D.A.; project administration, S.R.-M., and F.J.D.A.; funding acquisition, F.J.D.A.

Funding: BIFAP is funded and managed by the Spanish Agency for Medicines and Medical Devices. This study was supported by a research grant from Instituto de Salud Carlos III—Ministerio de Ciencia e Innovación (# PI16/01353), granted to F.d.A., cofounded by FEDER.

Acknowledgments: The authors would like to thank the excellent collaboration of primary care practitioners participating in BIFAP. We are also in debt with the staff members of the BIFAP Unit.

Conflicts of Interest: Luis A. García-Rodríguez has received research grants from Bayer and AstraZeneca for other projects. The rest of authors have no conflicts of interest to declare. The results: discussion, and conclusions are from the authors and do not necessarily represent the position of the Spanish Agency for Medicines and Medical Devices.

Appendix A Data Source

The study was carried out with data from BIFAP, a Spanish database that contains anonymized electronic records on clinical events, prescriptions, and laboratory tests, among others, registered by primary care physicians. For the present study, we used BIFAP-2016, which includes information from 7.6 million patients (38.6 million person-years) with a mean follow-up of 5.1 years, from 9 regions (out of 17) [21]. BIFAP presents the same distribution by sex and age as the Spanish population and has been validated through multiple pharmacoepidemiological studies [41,42].

Appendix B Selection of Cases and Controls

Incident AMI cases were initially searched through both codes and text on diagnosis fields and validated through manual review of clinical records. For disease classification, eight regions used the International Classification of Primary Care, version 2 (ICPC-2); and one used the International Classification of Diseases, version 9-Clinical Modification (ICD-9-CM). We conducted a search to identify all potential cases of AMI in the primary cohort, defined by the ICPC-2 code K75 (acute myocardial infarction), ICD-9-CM code 410.9 (myocardial infarction), or related terms (free-text) in the diagnosis field. Then, we grouped the potential cases identified into homogeneous subgroups according to the available information and extracted a random sample for each subgroup, manually validating a total of 600 cases reviewing the complete clinical history recorded in BIFAP. The case validation was carried out independently by two of the investigators (S.R.-M., D.G.-B.) who were blinded to any drug exposure. Discrepancies were settled by the entire research group, finally reaching a positive predictive value (PPV) of 87.2% (95% CI: 84.1–89.8%).

Appendix C Multiple Imputation by Chained Equations (MICE) Models

Multiple imputation is a statistical method that allows the assignment of a value to variables with missing information. The imputed values are sampled from their predictive distribution based on the observed data. Patterns of missing values are classified into three categories; “missing completely at random (MCAR)”, “missing at random (MAR)” and “missing not at random (MNAR)”. Often, imputing values with a MNAR pattern can give misleading results so before deciding to perform a multiple imputation model, researchers have to carefully study the patterns of missingness in order to rule out such a pattern. In this study, we explored the characteristics of the missing values and their relations with the observed data, and finally we accepted a MAR pattern.

Among the study population (N = 23,616), there were missing values for smoking (34.7%), Body Mass Index (BMI) (20.1%) and serum uric acid (SUA) level (12.1%). Missing values of smoking and BMI were related inversely with other cardiovascular risk factors as history of heart failure or diabetes, which may be explained by the greater tendency of the primary care physician to record exposure to...
tobacco or BMI in patients with comorbidities linked to these risk factors. The registry of SUA values, however, was strongly associated with the diagnosis of hyperuricemia or gout and treatment with urate lowering therapies (ULT).

To address missing values, we ran a multiple imputation by chained equations (MICE) model. The MICE model ran n-times for each variable to impute with k-cycles of stabilization every time. In this case, we set the model to run 20 times, creating 20 imputed databases, and 10 cycles to stabilize the variance before creating one imputed database. The MICE model successfully imputed all the missing values. In order to test the performance of the model, two sensitivity analyses were carried out: First, we plotted the distribution and density of all values (observed + imputed), observing that the imputed values followed the original distribution of the observed data in each variable (Figure A1 show this for SUA levels); and second, we performed a complete data analysis and then compared it to the ones with the imputed values and observed that the main estimators barely changed, supporting our initial assumption of a MAR pattern.

Figure A1. Density plots of observed, imputed and completed values for SUA levels.

References

1. Abeles, A.M.; Pillinger, M.H. Gout and cardiovascular disease: Crystallized confusion. Curr. Opin. Rheumatol. 2019, 31, 118–124. [CrossRef]
2. Landolfo, M.; Borghi, C. Hyperuricaemia and vascular risk: The debate continues. Curr. Opin. Cardiol. 2019, 34, 399–405. [CrossRef]
3. Roddy, E.; Doherty, M. Epidemiology of gout. Arthritis Res. Ther. 2010, 12, 223. [CrossRef]
4. Choi, H.K.; Curhan, G. Independent impact of gout on mortality and risk for coronary heart disease. Circulation 2007, 116, 894–900. [CrossRef]
5. Richette, P.; Latourte, A.; Bardin, T. Cardiac and renal protective effects of urate-lowering therapy. Rheumatology (Oxford) 2018, 57, i47–i50. [CrossRef]
6. Richette, P.; Doherty, M.; Pascual, E.; Barskova, V.; Becce, F.; Castañeda-Sanabria, J.; Coyfish, M.; Guillot, S.; Jansen, T.L.; Janssens, H. 2016 updated EULAR evidence-based recommendations for the management of gout. Ann. Rheum. Dis. 2017, 76, 9–42. [CrossRef] [PubMed]
7. Khanna, D.; Fitzgerald, J.D.; Khanna, P.P.; Bae, S.; Singh, M.K.; Neogi, T.; Pillinger, M.H.; Merill, J.; Lee, S.; Prakash, S. 2012 American College of Rheumatology guidelines for management of gout. Part I: Systematic nonpharmacologic and pharmacologic therapeutic approaches to hyperuricemia. *Arthritis Care Res. (Hoboken)* 2012, 64, 1431–1446. [CrossRef] [PubMed]

8. Stamp, L.; Dalbeth, N. Urate-lowering therapy for asymptomatic hyperuricaemia: A need for caution. *Semin. Arthritis Rheum.* 2017, 46, 457–464. [CrossRef] [PubMed]

9. Paul, B.J.; Anoopkumar, K.; Krishnan, V. Asymptomatic hyperuricemia: Is it time to intervene? *Clin. Rheumatol.* 2017, 36, 2637–2644. [CrossRef] [PubMed]

10. Struthers, A.; Shearer, F. Allopurinol: Novel indications in cardiovascular disease. *Heart* 2012, 98, 1543–1545. [CrossRef] [PubMed]

11. De Abajo, F.J.; Gil, M.J.; Rodríguez, A.; García-Poza, P.; Álvarez, A.; Bryant, V.; García-Rodríguez, L.A. Allopurinol use and risk of non-fatal acute myocardial infarction. *Heart* 2015, 101, 679–685. [CrossRef] [PubMed]

12. Grimaldi-Bensouda, L.; Alpas, A.; Aubrun, E.; Danchin, N.; Rossignol, M.; Abenhaim, L.; Richette, P.; PGRx MI Group. Impact of allopurinol use on risk of myocardial infarction. *Ann. Rheum. Dis.* 2015, 74, 836–842. [CrossRef] [PubMed]

13. Larsen, K.S.; Pottegard, A.; Lindegaard, H.M.; Hallas, J. Effect of allopurinol on cardiovascular outcomes in hyperuricemic patients: A cohort study. *Am. J. Med.* 2016, 129, 299–306. [CrossRef] [PubMed]

14. Singh, J.A.; Ramachandaran, R.; Yu, S.; Curtis, J.R. Allopurinol use and the risk of acute cardiovascular events in patients with gout and diabetes. *BMC Cardiovasc. Disord.* 2017, 17, 76. [CrossRef] [PubMed]

15. Chen, J.H.; Lan, J.L.; Cheng, C.F.; Liang, W.M.; Lin, H.Y.; Tsay, G.J.; Yeh, W.T.; Pan, W.H. Effect of Urate-lowering Therapy on the Risk of Cardiovascular Disease and All-cause Mortality in Patients with Gout: A Case-matched Cohort Study. *J. Rheumatol.* 2015, 42, 1694–1700. [CrossRef]

16. Seltoft Larsen, K.; Pottegard, A.; Lindegaard, H.M.; Hallas, J. Impact of Urate Level on Cardiovascular Risk in Allopurinol Treated Patients. A Nested Case-Control Study. *PLoS ONE* 2016, 11, e0146172.

17. Kim, S.C.; Schneeweiss, S.; Choudhry, N.; Liu, J.; Glynn, R.J.; Solomon, D.H. Effects of xanthine oxidase inhibitors on cardiovascular disease in patients with gout: A cohort study. *Am. J. Med.* 2015, 128, 653-e7. [CrossRef] [PubMed]

18. Zhang, T.; Pope, J.E. Cardiovascular effects of urate-lowering therapies in patients with chronic gout: A systematic review and meta-analysis. *Rheumatology (Oxford)* 2017, 56, 1144–1153. [CrossRef]

19. Kok, V.C.; Horng, J.T.; Chang, W.S.; Hong, Y.F.; Chang, T.H. Allopurinol therapy in gout patients does not associate with beneficial cardiovascular outcomes: A population-based matched-cohort study. *PLoS ONE* 2014, 9, e99102. [CrossRef]

20. Richette, P.; Perez-Ruiz, F.; Doherty, M.; Jansen, T.L.; Nuki, G.; Pascual, E.; Punzi, L.; So, A.K.; Bardin, T. Improving cardiovascular and renal outcomes in gout: What should we target? *Nat. Rev. Rheumatol.* 2014, 10, 654–661. [CrossRef]

21. BIFAP: Base de Datos para la Investigación Farmacoepidemiológica en Atención Primaria. Available online: http://www.bifap.org (accessed on 15 April 2019).

22. Ray, W.A. Evaluating medication effects outside of clinical trials: New-user designs. *Am. J. Epidemiol.* 2003, 158, 915–920. [CrossRef] [PubMed]

23. Altman, D.G.; Bland, J.M. Interaction revisited: The difference between two estimates. *BMJ* 2003, 326, 219. [CrossRef] [PubMed]

24. Azur, M.J.; Stuart, E.A.; Frangakis, C.; Leaf, P.J. Multiple imputation by chained equations: What is it and how does it work? *Int. J. Methods Psychiatr. Res.* 2011, 20, 40–49. [CrossRef] [PubMed]

25. Grayson, P.C.; Kim, S.Y.; LaValley, M.; Choi, H.K. Hyperuricemia and incident hypertension: A systematic review and meta-analysis. *Arthritis Care Res. (Hoboken)* 2011, 63, 102–110. [CrossRef] [PubMed]

26. Wei, L.; Mackenzie, I.S.; Chen, Y.; Struthers, A.D.; MacDonald, T.M. Impact of allopurinol use on urate concentration and cardiovascular outcome. *Br. J. Clin. Pharmacol.* 2011, 71, 600–607. [CrossRef] [PubMed]

27. Bredemeier, M.; Lopes, L.M.; Eisenreich, M.A.; Hickmann, S.; Bongiorno, G.K.; d’Avila, R.; Morsch, A.L.; da Silva Stein, F.; Campos, G.G.D. Xanthine oxidase inhibitors for prevention of cardiovascular events: A systematic review and meta-analysis of randomized controlled trials. *BMC Cardiovasc. Disord.* 2018, 18, 24. [CrossRef]
28. Desai, R.J.; Franklin, J.M.; Spoendlin-Allen, J.; Solomon, D.H.; Danaei, G.; Kim, S.C. An evaluation of longitudinal changes in serum urate levels and associated risk of cardio-metabolic events and renal function decline in gout. *PLoS ONE* **2018**, *13*, e0193622. [CrossRef]

29. Pérez-Ruiz, F.; Richette, P.; Stack, A.G.; Gurunath, R.K.; García de Yébenes, M.J.; Carmona, L. Failure to reach uric acid target of <0.36 mmol/L in hyperuricaemia of gout is associated with elevated total and cardiovascular mortality. *RMD Open* **2019**, *5*, e001015. [CrossRef]

30. Wu, J.; Lei, G.; Wang, X.; Tang, Y.; Cheng, H.; Jian, G.; Wu, X.; Wang, N. Asymptomatic hyperuricemia and coronary artery disease in elderly patients without comorbidities. *Oncotarget* **2017**, *8*, 80688–80699. [CrossRef]

31. Rajendra, N.S.; Ireland, S.; George, J.; Belch, J.J.; Lang, C.C.; Struthers, A.D. Mechanistic insights into the therapeutic use of high-dose allopurinol in angina pectoris. *J. Am. Coll. Cardiol.* **2011**, *58*, 820–828. [CrossRef]

32. George, J.; Carr, E.; Davies, J.; Belch, J.J.; Struthers, A.D. High-dose allopurinol improves endothelial dysfunction by profoundly reducing vascular oxidative stress and not by lowering uric acid. *Circulation* **2006**, *114*, 2508–2516. [CrossRef] [PubMed]

33. Kanbay, M.; Segal, M.; Afsar, B.; Kang, D.H.; Rodriguez-Iturbe, B.; Johnson, R.J. The role of uric acid in the pathogenesis of human cardiovascular disease. *Heart* **2013**, *99*, 759–766. [CrossRef] [PubMed]

34. Kang, D.H.; Park, S.K.; Lee, I.K.; Johnson, R.J. Uric acid-induced C-reactive protein expression: Implication on cell proliferation and nitric oxide production of human vascular cells. *J. Am. Soc. Nephrol.* **2005**, *16*, 3553–3562. [CrossRef]

35. Halevy, S.; Ghislain, P.D.; Mockenhaupt, M.; Fagot, J.P.; Bouwes Bavinck, J.N.; Sidoroff, A.; Naldi, L.; Dunant, A.; Viboud, C.; Roujeau, J.C.; et al. Allopurinol is the most common cause of Stevens-Johnson syndrome and toxic epidermal necrolysis in Europe and Israel. *J. Am. Acad. Dermatol.* **2008**, *58*, 25–32. [CrossRef] [PubMed]

36. Yang, C.Y.; Chen, C.H.; Deng, S.T.; Huang, C.S.; Lin, Y.J.; Chen, Y.J.; Wu, C.Y.; Hung, S.I.; Chung, W.H. Allopurinol Use and Risk of Fatal Hypersensitivity Reactions: A Nationwide Population-Based Study in Taiwan. *JAMA Intern. Med.* **2015**, *175*, 1550–1557. [CrossRef]

37. Keller, S.F.; Lu, N.; Blumenthal, K.G.; Rai, S.K.; Yokose, C.; Choi, J.W.J.; Kim, S.C.; Zhang, Y.; Choi, H.K. Racial/ethnic variation and risk factors for allopurinol associated severe cutaneous adverse reactions: A cohort study. *Ann. Rheum. Dis.* **2018**, *77*, 1187–1193. [CrossRef]

38. Rodríguez-Martin, S.; Martin-Merino, E.; Lerma, V.; Rodriguez-Miguel, A.; González, O.; González-Herrada, C.; Ramirez, E.; de Abajo, F.J.; Bellón, T. Incidence of Stevens-Johnson syndrome/toxic epidermal necrolysis among new users of different individual drugs in a European population: A case-population study. *Eur. J. Clin. Pharmacol.* **2019**, *75*, 237–246.

39. Rothman, K.J.; Greenland, S.; Lash, T.L. *Modern Epidemiology*, 3rd ed.; Lippincott Williams & Wilkins: Philadelphia, PA, USA, 2008; pp. 111–127.

40. Vittinghoff, E.; Glidden, D.V.; Shiboski, S.C.; McCulloch, C.E. *Regression Methods in Biostatistics, Linear, Logistic, Survival, and Repeated Measures Models*, 2nd ed.; Springer: Berlin/Heidelberg, Germany, 2012; pp. 431–467.

41. De Abajo, F.J.; Gil, M.J.; García Pozas, P.; Bryant, V.; Oliva, B.; Timoner, J.; García-Rodríguez, L.A. Risk of nonfatal acute myocardial infarction associated with non-steroidal antiinflammatory drugs, non-narcotic analgesics and other drugs used in osteoarthritis: A nested case-control study. *Pharmacoepidemiol. Drug Saf.* **2014**, *23*, 1128–1138. [CrossRef]

42. García-Pozas, P.; de Abajo, F.J.; Gil, M.J.; Chacón, A.; Bryant, V.; García-Rodríguez, L.A. Risk of ischemic stroke associated with non-steroidal anti-inflammatory drugs and paracetamol: A population-based case-control study. *J. Thromb. Haemost.* **2015**, *13*, 708–718. [CrossRef]